Nippon India Pharma Fund - Bonus - Direct Plan

Other Plans and Options
  • 1.03 %Nav, as on 30-01-2025

  • Previous Nav

  • Net Change on 30-01-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Bonus | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Nippon India Pharma Fund - Direct Plan Bonus Plan - Bonus -8.73 -6.28 16.72 19.72 25.58 18.20
BSE Health Care - TRI -7.85 -3.44 27.07 21.15 24.96 15.70
BSE SENSEX - TRI -1.88 -3.89 9.22 11.69 14.78 13.45

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Bonus Plan - Bonus Jan 01, 2013 16.72 19.72 25.58 0.91 8,914.89

Fund Holdings as on 31-December-2024

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Lupin Limited

  • Dr. Reddy's Laboratories Limited

  • Cipla Limited

  • Apollo Hospitals Enterprise Limited

  • Vijaya Diagnostic Centre Limited

  • MedPlus Health Services Limited

  • Ajanta Pharma Limited

  • Gland Pharma Limited

  • Abbott India Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Aurobindo Pharma Limited

  • Mankind Pharma Limited

  • Zydus Lifesciences Limited

  • Narayana Hrudayalaya Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Triparty Repo

  • Torrent Pharmaceuticals Limited

  • Pfizer Limited

  • Fortis Healthcare Limited

  • Thyrocare Technologies Limited

  • Alkem Laboratories Limited

  • Sanofi India Limited

  • Orchid Pharma Limited

  • Suraksha Diagnostic Limited

  • Sanofi Consumer Healthcare India Limited

  • Syngene International Limited

  • Dr. Lal Path Labs Limited

  • Indoco Remedies Limited

  • Sai Life Sciences Limited

  • AstraZeneca Pharma India Limited

  • Healthcare Global Enterprises Limited

  • Emcure Pharmaceuticals Limited

  • IPCA Laboratories Limited

  • Krishna Institute Of Medical Sciences Limited

  • Concord Biotech Limited

  • Cash Margin - CCIL

  • Net Current Assets

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Business Support

View More

Fund Manager

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 01-Jan-2013 and currently has an AUM of ₹8,914.89 crore. Nippon India Pharma Fund is benchmarked against BSE Health Care - TRI as primary index and BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended up ₹5.4(1.03%)yesterday to ₹531.4891.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan .

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097